Citations

Clear

9 citation(s) found for "Lin, Jung-Yi".

Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis and Prior Mediastinal Radiation: A Meta-Analysis of Short-Term and 1-Year Outcomes
Elbenawi, Hossam , Mostafa, N., Dahik, Buseyna, Botros, Michael, Eisa, Mahmoud , Zreigh, Sofian , Kalaiger, Abdul M., Almaadawy, Omar , Youssef, Mohammed, Zaaya, Morad, Stephens, R. E., Ghanim, Mostafa, Lin, Chien‐Jung, Elgendy, I S L A M, Goldsweig, Andrew M., Mostafa, Naydeen , Stephens, Richard, Kalaiger, Abdul Mukhtadir , Abdelgalil, Mahmoud Shaaban , Hamed, Belal Mohamed , Botros, Michael, Stephens, Richard, Elgendy, Islam Y. , Goldsweig, Andrew M.

Mayo Clinic

Cardiology in Review | March 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001263 | PMID 41913240 Get It

Mediastinal radiation potentiates aortic stenosis and complicates its treatment. We compared the short and midterm-outcomes with transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with prior mediastinal radiation. Electronic databases were searched from inception through December 2024. Dichotomous outcomes were pooled as risk ratios (RRs), and continuous outcomes were pooled as mean differences (MDs) with respective 95% confidence intervals (CIs). Six observational studies were identified, including 2458 TAVR patients and 1873 SAVR patients. In the short-term, TAVR was associated with lower rate of mortality (RR: 0.54; 95% CI: 0.34–0.88), atrial fibrillation (RR: 0.31; 95% CI: 0.15–0.65), acute kidney injury (RR: 0.75; 95% CI: 0.59–0.95), bleeding (RR: 0.37, 95% CI: 0.33–0.42), and shorter length of hospital stay (MD: −4.30; 95% CI: −5.45 to −3.15). One-year mortality was comparable between the 2 groups (RR: 1.04; 95% CI: 0.50–2.13). This meta-analysis of observational studies of patients with prior mediastinal radiation demonstrated that TAVR was associated with better short-term outcomes compared to SAVR. While 1-year mortality appeared similar between the 2 interventions, this finding should be interpreted with caution. However, randomized controlled trials are needed to validate these findings.
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care
Clevenger, Carolyn , Karlawish, Jason , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, María C. , Atri, Alireza , Dickerson, Bradford Clark , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.14333 | PMID 39713942 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. Through a modified‐Delphi approach and guideline‐development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient‐centered evaluation process. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care
Clevenger, Carolyn , Karlawish, Jason , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, María C. , Dickerson, Bradford Clark , Atri, Alireza , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14337 | PMID 39713957 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or a related dementia (ADRD) are two decades old. This evidence‐based guideline was developed to empower all clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. An expert workgroup conducted a review of 7374 publications (133 met inclusion criteria) and developed recommendations as steps in an evaluation process. This summary briefly reviews core recommendations and details specialist recommendations of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations. If clinicians use the recommendations in this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations appropriate for specialty practice settings, forming key elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD‐ADRD): Validated clinical assessment instruments
Clevenger, Carolyn , Karlawish, Jason , Knopman, David S. , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, Marı́a C., Carrillo, María C. , Atri, Alireza , Dickerson, Bradford Clark , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14335 | PMID 39713939 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's Disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. As part of the modified Delphi approach and guideline development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient‐centered evaluation process. The workgroup provided a summary of validated instruments to measure symptoms in daily life (including cognition, mood and behavior, and daily function) and to test for signs of cognitive impairment in the office. This article distills this information to provide a resource to support clinicians in the implementation of this approach in clinical practice. The companion articles provide context for primary care and specialty clinicians with regard to how to fit these instruments into the workflow and actions to take when integration of performance on these instruments with clinical profile and clinician judgment support potential cognitive impairment.
Multicolumn Nanoflow Liquid Chromatography with Accelerated Offline Gradient Generation for Robust and Sensitive Single-Cell Proteome Profiling
Xie, Xiaofeng , Huang, Siqi , Johnston, S. Madisyn, Hovanski, Simon, Robinson, Abigail, Webber, Kei G. I., Lin, Hsien‐Jung L. , Pandey, Akhilesh , Lin, Hsien-Jung L , Pandey, Akhilesh , Kelly, Ryan T , Truong, Thy , Mun, Dong‐Gi

Mayo Clinic

Analytical Chemistry | June 25, 2024 | Volume: 96 | Issue: 26 | Pages: 10534-10542

10.1021/acs.analchem.4c00878 | PMID 38915247 Get It

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Etra, Aaron , Gergoudis, Stephanie, Morales, George , Spyrou, Nikolaos , Shah, Jay , Kowalyk, Steven, Ayuk, Francis , Baez, Janna , Chanswangphuwana, Chantiya , Chen, Yi‐Bin , Choe, Hannah , DeFilipp, Zachariah , Gandhi, Isha , Holler, Ernst , Kapoor, Urvi , Kitko, Carrie L. , Lin, Jung-Yi, Pawarode, Attaphol , Rösler, Wolf, Schechter, Tal , Hyfte, Grace Van , Weber, Daniela , Wölfl, Matthias , Young, Rachel , Özbek, Umut , Ferrara, James L.M. , Hexner, Elizabeth , Lin, Jung-Yi , Merli, Pietro , Pulsipher, Michael A. , Qayed, Muna , Levine, John E , Spyrou, Nikolaos , Hexner, Elizabeth O. , Hogan, William J. , Kraus, Sabrina , Malki, Monzr M. Al , Reshef, Ran , Levine, John E.

Mayo Clinic

Blood Advances | June 23, 2022 | Volume: 6 | Issue: 12 | Pages: 3707-3715

10.1182/bloodadvances.2022007296 | PMID 35443021 Get It

Abstract We used a rigorous PRoBE (prospective-specimen collection, retrospective-blinded-evaluation) study design to compare the ability of biomarkers of systemic inflammation and biomarkers of gastrointestinal (GI) tissue damage to predict response to corticosteroid treatment, the incidence of clinically severe disease, 6-month nonrelapse mortality (NRM), and overall survival in patients with acute graft-versus-host disease (GVHD). We prospectively collected serum samples of newly diagnosed GVHD patients (n = 730) from 19 centers, divided them into training (n = 352) and validation (n = 378) cohorts, and measured TNFR1, TIM3, IL6, ST2, and REG3α via enzyme-linked immunosorbent assay. Performances of the 4 strongest algorithms from the training cohort (TNFR1 + TIM3, TNFR1 + ST2, TNFR1 + REG3α, and ST2 + REG3α) were evaluated in the validation cohort. The algorithm that included only biomarkers of systemic inflammation (TNFR1 + TIM3) had a significantly smaller area under the curve (AUC; 0.57) than the AUCs of algorithms that contained ≥1 GI damage biomarker (TNFR1 + ST2, 0.70; TNFR1 + REG3α, 0.73; ST2 + REG3α, 0.79; all P < .001). All 4 algorithms were able to predict short-term outcomes such as response to systemic corticosteroids and severe GVHD, but the inclusion of a GI damage biomarker was needed to predict long-term outcomes such as 6-month NRM and survival. The algorithm that included 2 GI damage biomarkers was the most accurate of the 4 algorithms for all endpoints.
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
Gergoudis, Stephanie, DeFilipp, Zachariah , Özbek, Umut , Sandhu, Karamjeet , Etra, Aaron , Choe, Hannah , Kitko, Carrie L. , Ayuk, Francis , Aziz, Mina, Baez, Janna , Ben-David, Kaitlyn , Bunworasate, Udomsak , Gandhi, Isha , Holler, Ernst , Kasikis, Stelios, Kowalyk, Steven, Lin, Jung-Yi, Morales, George , Nakamura, Ryotaro , Rösler, Wolf, Srinagesh, Hrishikesh K. , Young, Rachel , Chen, Yi‐Bin , Ferrara, James L.M. , Levine, John E. , Levine, John E , Hexner, Elizabeth O. , Hogan, William J. , Merli, Pietro , Reshef, Ran

Mayo Clinic

Blood Advances | December 10, 2020 | Volume: 4 | Issue: 24 | Pages: 6098-6105

10.1182/bloodadvances.2020003336 | PMID 33351103 Get It

Abstract Steroid-refractory (SR) acute graft-versus-host disease (GVHD) remains a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT), but its occurrence is not accurately predicted by pre-HCT clinical risk factors. The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP) identifies patients who are at high risk for developing SR GVHD as early as 7 days after HCT based on the extent of intestinal crypt damage as measured by the concentrations of 2 serum biomarkers, suppressor of tumorigenesis 2 and regenerating islet-derived 3α. We conducted a multicenter proof-of-concept “preemptive” treatment trial of α-1-antitrypsin (AAT), a serine protease inhibitor with demonstrated activity against GVHD, in patients at high risk for developing SR GVHD. Patients were eligible if they possessed a high-risk MAP on day 7 after HCT or, if initially low risk, became high risk on repeat testing at day 14. Thirty high-risk patients were treated with twice-weekly infusions of AAT for a total of 16 doses, and their outcomes were compared with 90 high-risk near-contemporaneous MAGIC control patients. AAT treatment was well tolerated with few toxicities, but it did not lower the incidence of SR GVHD compared with controls (20% vs 14%, P = .56). We conclude that real-time biomarker-based risk assignment is feasible early after allogeneic HCT but that this dose and schedule of AAT did not change the incidence of SR acute GVHD. This trial was registered at www.clinicaltrials.gov as #NCT03459040.
The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
Özbek, Umut , Kapoor, Urvi , Ayuk, Francis , Aziz, Mina, Ben-David, Kaitlyn , Choe, Hannah , DeFilipp, Zachariah , Etra, Aaron , Hartwell, Matthew J. , Kowalyk, Steven, Lin, Jung-Yi, Major-Monfried, Hannah , Mielke, Stephan , Morales, George , Ordemann, Rainer, Reddy, Pavan, Roesler, Wolf, Sandhu, Karamjeet , Schechter‐Finkelstein, Tal, Weber, Daniela , Wölfl, Matthias , Young, Rachel , Ferrara, James L.M. , Mielke, Stephan , Srinagesh, Hrishikesh K. , Grupp, Stephan A. , Hexner, Elizabeth O. , Hogan, William J. , Kitko, Carrie L. , Merli, Pietro , Pulsipher, Michael A. , Qayed, Muna , Reshef, Ran , Shah, Jay, Sigel, Keith Magnus , Wudhikarn, Kitsada , Levine, John E.

Mayo Clinic

Blood | February 14, 2020 | Volume: 134 | Issue: Supplement_1 | Pages: 367-367

10.1182/blood-2019-122011 Get It

Systemic glucocorticoids are the principal treatment for acute graft-versus-host disease (GVHD), which remains the major cause of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT). However, there are no validated biomarkers that measure a patient's response to glucocorticoid therapy, and thus response is evaluated by the change in clinical symptom severity. A major weakness in the predictive power of clinical responses is that changes to all organs are weighted equally even though the major driver of NRM is irreversible damage to the crypts of the GI tract. Recent studies from the Mount Sinai Acute GVHD International Consortium (MAGIC) have validated an algorithm probability (MAP) that combines serum concentrations of two biomarkers of GVHD (REG3α and ST2) to generate an estimated probability of 6 month NRM for individual patients. The MAP has been considered a "liquid biopsy" that estimates the damage caused by GVHD to crypts throughout the lower GI tract (Hartwell et al., JCI Insight, 2017; Major-Monfried et al., Blood, 2018). We hypothesized that the change in MAP between start of treatment and 28 days later could serve as a response biomarker for GVHD and might compare favorably to the change in clinical symptoms that measures response to GVHD treatment, which is widely used as a surrogate for long term survival and is the primary endpoint in most GVHD treatment trials (Martin et al., BBMT, 2009; MacMillan et al., Blood, 2010). We prospectively collected serum samples and clinical staging from 368 sequential HCT patients who received systemic treatment for acute GVHD in one of 20 MAGIC centers between January 2016 and February 2018. We measured the serum concentrations of REG3α and ST2 before and after systemic therapy for acute GVHD and computed MAPs, the changes in MAPs, and clinical responses for each patient. MAPs of patients who experienced 6 month NRM showed significantly greater increases than MAPs of patients who survived (p=0.0004). In patients whose MAPs at the start of treatment were low (Ann Arbor 1, MAP < 0.141) or intermediate (Ann Arbor 2, 0.141 ≤ MAP ≤ 0.290), 6 month NRM clustered among those who had the greatest increases in MAP after 28 days (Fig 1A,B). In patients with high MAPs at the start of treatment (Ann Arbor 3, MAP > 0.290), those who survived tended to have the largest decreases in MAP (Fig 1C). These changes in MAP suggested crossing a single threshold could predict risk of mortality. We found that patients whose MAPs rose above a threshold MAP of 0.290 (5% of Ann Arbor 1, 27% of Ann Arbor 2) had significantly worse survival compared to those who remained below it, whereas the large number patients with initially high MAPs that remained above the threshold (66% of Ann Arbor 3) had a large increases in mortality (Fig 2). When measured at day 28, the MAP was significantly more accurate in predicting NRM than the gold standard of the clinical response, with areas under the receiver operating characteristic curve (AUC) of 0.86 and 0.70, respectively (p<0.0001). An algorithm that combined clinical response with biomarkers generated the same AUC as the MAP alone (0.83 v 0.86, p = NS). We next tested whether the same MAP threshold of 0.290 could predict risk within clinical response subsets. A significant minority (10%) of clinical responders had high MAPs and experienced three-fold greater NRM than those with low MAPs (40% v 12%, p<0.0001) whereas the majority (57%) of non-responders had low MAPs and experienced almost three-fold lower NRM than those with high MAPs (24% v 65%, p<0.0001) (Fig 3). Thus the MAP provides important prognostic information over and above the change in clinical symptoms, further stratifying both responders and non-responders at four weeks of treatment. The MAP threshold classified patients both with and without significant lower GI symptoms because the MAP is a more specific measure of irreversible cryptic damage in patients with copious diarrhea and more sensitive in patients with less than 0.5 liters of daily diarrhea (Fig 4). We conclude that the MAP is, to our knowledge, the first validated laboratory test to serve as response biomarker for the treatment for acute GVHD and a more accurate predictor of survival than clinical response after four weeks of treatment. The MAP may serve as a novel endpoint and an important complement to changes in clinical symptom severity in future trials of GVHD treatment. Disclosures Srinagesh: National Institutes of Health: Research Funding. Ozbek:Viracor: Patents & Royalties: Biomarker Patent. Ayuk:Novartis: Honoraria, Other: Advisory Board, Research Funding. Aziz:Doris Duke Charitable Foundation: Research Funding. Defilipp:Incyte: Research Funding. Grupp:Novartis: Consultancy, Research Funding; Roche: Consultancy; GSK: Consultancy; CBMG: Consultancy; Novartis: Research Funding; Kite: Research Funding; Servier: Research Funding; Jazz: Other: study steering committees or scientific advisory boards; Adaptimmune: Other: study steering committees or scientific advisory boards; Cure Genetics: Consultancy; Humanigen: Consultancy. Hexner:novartis: Research Funding. Kitko:Mallinckrodt: Honoraria; Novartis: Consultancy, Honoraria. Mielke:EBMT/EHA: Other: Travel support; ISCT: Other: Travel support; Miltenyi: Consultancy, Honoraria, Other: Travel and speakers fee (via institution), Speakers Bureau; Jazz Pharma: Honoraria, Other: Travel support, Speakers Bureau; IACH: Other: Travel support; Kiadis Pharma: Consultancy, Honoraria, Other: Travel support (via institution), Speakers Bureau; DGHO: Other: Travel support; Bellicum: Consultancy, Honoraria, Other: Travel (via institution); GILEAD: Consultancy, Honoraria, Other: travel (via institution), Speakers Bureau; Celgene: Honoraria, Other: Travel support (via institution), Speakers Bureau. Merli:Sobi: Consultancy; Amgen: Honoraria; Novartis: Honoraria; Bellicum: Consultancy. Pulsipher:Amgen: Other: Lecture; Miltenyi: Research Funding; Bellicum: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz: Other: Education for employees; CSL Behring: Membership on an entity's Board of Directors or advisory committees; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Medac: Honoraria. Qayed:Bristol-Myers Squibb: Honoraria. Reshef:Pfizer: Consultancy; Magenta: Consultancy; Kite: Consultancy, Research Funding; Atara: Consultancy, Research Funding; BMS: Consultancy; Pharmacyclics: Consultancy, Research Funding; Incyte: Consultancy, Research Funding; Celgene: Research Funding; Shire: Research Funding. Levine:Incyte: Consultancy, Research Funding; Biogen: Other: non-financial support; Viracor: Patents & Royalties: biomarker patent; Ironwood: Honoraria; bluebird bio: Consultancy; National Cancer Institute: Research Funding; Novartis: Honoraria; Kamada: Research Funding. Ferrara:National Institutes of Health: Research Funding; ViraCor: Consultancy; Incyte: Consultancy; Kamada: Consultancy; Mallinckrodt: Consultancy; Enlivex: Consultancy; Xenikos: Consultancy; CSL Behring: Consultancy.
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
Srinagesh, Hrishikesh K. , Özbek, Umut , Kapoor, Urvi , Ayuk, Francis , Aziz, Mina, Ben-David, Kaitlyn , Choe, Hannah , DeFilipp, Zachariah , Etra, Aaron , Hartwell, Matthew J. , Karol, Alexander B. , Kasikis, Stelios, Kitko, Carrie L. , Kowalyk, Steven, Lin, Jung-Yi , Major-Monfried, Hannah , Mielke, Stephan , Morales, George , Ordemann, Rainer, Reddy, Pavan , Reshef, Ran , Rösler, Wolf, Sandhu, Karamjeet , Schechter, Tal , Weber, Daniela , Wölfl, Matthias , Wudhikarn, Kitsada , Young, Rachel , Levine, John E. , Ferrara, James L.M. , Reshef, Ran , Lin, Jung-Yi , Levine, John E , Mielke, Stephan , Grupp, Stephan A. , Hexner, Elizabeth O. , Hogan, William J. , Merli, Pietro , Pulsipher, Michael A. , Qayed, Muna , Shah, Jay, Sigel, Keith Magnus

Mayo Clinic

Blood Advances | December 9, 2019 | Volume: 3 | Issue: 23 | Pages: 4034-4042

10.1182/bloodadvances.2019000791 | PMID 31816061 Get It

Key Points The MAGIC algorithm probability, computed from 2 serum biomarkers, predicts mortality in all GVHD grades after 4 weeks of treatment. Dynamic changes in the MAGIC algorithm probability occur within all biomarker risk groups and can guide therapy.